Glucagon-Like Peptide-1 Receptor Agonists and Other Drugs for Metabolic Dysfunction-Associated Steatotic Liver Disease: What Is the Update?

Nov 18 2024
Convention Center: Room 31 B
7:00 AM - 7:45 AM
Ticketed Event

World Class Speakers

Kathleen E Corey, MD, MPH, MMSc
Discussion Leader

Kathleen E Corey, MD, MPH, MMSc

Massachusetts General Hospital
AD
Discussion Leader

Amreen Dinani, MD FRCPC

Duke University School of Medicine

Description

In this session, experts update attendees on the latest research and clinical advancements concerning the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and other pharmaceuticals for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Presenters provide valuable insights into the mechanisms underlying these treatments and discuss how to apply this knowledge effectively in clinical practice. Additionally, experts instruct attendees how to develop the ability to critically evaluate emerging trends and evidence, thereby promoting evidence-based decision-making for MASLD management.

Journey Maps

Objectives

  • Review the latest developments in the use of GLP-1 RAs and other pharmacologic agents for the management of MASLD.
  • Describe the evolving landscape of pharmaceutical interventions related to GLP-1 RAs and their potential impact on MASLD, including the latest research findings, clinical trials, and real-world applications.
  • Discuss the promising role of GLP-1 RAs and other drugs as potential therapeutic options for MASLD.